Alpa Laboratories Limited (ALPA) AI Stock Analysis

3 Followers

Alpa Laboratories Limited

(NSE:ALPA)

Select Model

Rating:57Neutral

Price Target:INR 58.00▲(4.30% Upside)

Action:reiterated

Date:09/06/26

Solid financial performance led by balance sheet strength is the primary positive driver, offset by bearish technical signals and elevated valuation multiples.

Positive Factors

Conservative balance sheetVery low leverage gives Alpa Laboratories financial resilience and limits the burden of interest or refinancing costs. Steadily growing equity also indicates retained capital accumulation, supporting asset growth and preserving flexibility to fund operations through a weaker earnings period.

Negative Factors

Latest revenue declineThe latest revenue contraction, following an uneven growth pattern, indicates that demand or execution has not translated into consistently expanding sales. Persistent top-line volatility can limit operating leverage, complicate planning, and weaken the visibility of earnings over the next several quarters.

Alpa Laboratories Limited (ALPA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 1.19B
Dividend Yield: ―
Average Volume (3M): 4,237
Price to Earnings (P/E): 33.3
Beta (1Y): 1.29
Revenue Growth: 0.46%
EPS Growth: -83.31%
Country: India
Employees: 457
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Alpa Laboratories Limited Business Overview & Revenue Model

Company Description

Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-gra...

Alpa Laboratories Limited Financial Statement Overview

Summary

Strong balance sheet with growing equity to 1.86B and minimal debt supports stability (sub-score 85), while income growth to 150M net income and cash flow improvements are offset by margin erosion and volatility (sub-scores 65 and 55).

Income Statement

65Positive

Balance Sheet

85Very Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	1.16B	1.06B	1.12B	1.09B	924.10M	1.11B
Gross Profit	243.95M	136.09M	193.99M	188.90M	307.44M	344.08M
EBITDA	75.79M	190.47M	281.01M	229.96M	174.43M	214.31M
Net Income	43.78M	150.10M	195.03M	167.76M	125.83M	140.92M
Balance Sheet
Total Assets	0	2.42B	2.23B	1.82B	1.67B	1.55B
Cash, Cash Equivalents and Short-Term Investments	1.38B	1.38B	1.13B	928.54M	808.42M	702.74M
Total Debt	0	25.08M	343.00K	52.47M	23.04M	58.47M
Total Liabilities	-1.86B	558.64M	511.59M	304.62M	326.92M	335.08M
Stockholders Equity	1.86B	1.86B	1.71B	1.52B	1.35B	1.22B
Cash Flow
Free Cash Flow	89.97M	84.84M	-21.42M	-27.36M	77.78M	77.49M
Operating Cash Flow	106.65M	124.37M	92.37M	36.49M	89.04M	99.40M
Investing Cash Flow	-144.58M	-143.01M	-35.13M	-133.36M	21.27M	-156.10M
Financing Cash Flow	22.40M	24.80M	-52.47M	25.83M	-37.93M	54.42M

Alpa Laboratories Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price55.61

Price Trends

50DMA57.34Negative

100DMA62.06Negative

200DMA64.29Negative

Market Momentum

MACD-0.51Negative

RSI51.71Neutral

STOCH66.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Neutral. The current price of 55.61 is above the 20-day moving average (MA) of 52.86, below the 50-day MA of 57.34, and below the 200-day MA of 64.29, indicating a neutral trend. The MACD of -0.51 indicates Negative momentum. The RSI at 51.71 is Neutral, neither overbought nor oversold. The STOCH value of 66.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ALPA.

Alpa Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ALPA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PAR	73Outperform	INR 1.46B	11.27	―	―	9.40%	34.12%
IN:BROOKS	61Neutral	INR 1.94B	2.59	―	―	-14.88%	431.30%
IN:ALPA	57Neutral	INR 1.17B	33.32	―	―	0.46%	-83.31%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BALPHARMA	49Neutral	INR 1.40B	20.03	―	1.33%	18.79%	-2.58%
IN:NECLIFE	44Neutral	INR 2.04B	-0.94	―	―	-99.53%	-41.93%
IN:BIOFILCHEM	41Neutral	INR 508.72M	106.15	―	―	9.31%	-82.71%

* General Sector Average

Performance Comparison

IN:ALPA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ALPA	Alpa Laboratories Limited	55.61	-24.36	-30.46%
IN:BALPHARMA	Bal Pharma Limited	90.10	11.30	14.34%
IN:BIOFILCHEM	Biofil Chemicals & Pharmaceuticals Ltd.	31.10	-8.68	-21.82%
IN:BROOKS	Brooks Laboratories Limited	64.23	-38.62	-37.55%
IN:NECLIFE	Nectar Lifesciences Ltd.	10.73	-3.91	-26.71%
IN:PAR	Par Drugs and Chemicals Limited	119.00	24.89	26.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Alpa Laboratories Limited AI Stock Analysis